AbstractObjective To examine the dosimetric advantages of three-dimensional (3D) computed tomography (CT)-guided interstitial brachytherapy (BT) for target volume and surrounding normal tissue in patients with locally advanced cervical cancer,and to provide a simple and effective clinical treatment approach.Methods A total of 52 patients who had poor tumor response to external beam radiotherapy (EBRT) with a residual tumor greater than 5 cm at the time of BT were included. The patients were treated by 3D CT-guided interstitial BT using a “hybrid” applicator comprised of uterine tandem and free metal needles. The high-risk clinical target volume (HR-CTV),intermediate-risk clinical target volume (IR-CTV),and organs at risk (OAR) were contoured. The total dose,including external beam radiotherapy and high dose-rate BT,was biologically normalized to conventional 2 Gy fractions (EQD2).D90 and D100 for both HR-CTV and IR-CTV,and D2 cc for the bladder,rectum,and sigmoid were analyzed. Results The mean D90 value for HR-CTV was 88.4±3.5 Gy. The D2 cc for the bladder,rectum,and sigmoid were 81.1±5.6,65.7±5.1,and 63.1±5.4 Gy,respectively.D2 cc ≤90 Gy for the bladder and D2 cc ≤70 Gy for the sigmoid wereobserved in all the patients.D2 cc ≤70 Gy for the rectum was observed in 89% of patients. Conclusions 3DCT-guided interstitial BT has a significant dosimetric advantage for target volume accompanied by few minor complications,and thereby may be clinically feasible for treating locally advanced cervical cancer. However,its long-term efficacy and possible toxicities will require further clinical observation.
Corresponding Authors:
Wang Tiejun,Email:wangtiejunjlu@163.com
Cite this article:
. CT-guided interstitial brachytherapy for locally advanced cervical cancer:introduction of the technique and report of dosimetry[J]. Chinese Journal of Radiation Oncology, 2017, 26(5): 550-554.
. CT-guided interstitial brachytherapy for locally advanced cervical cancer:introduction of the technique and report of dosimetry[J]. Chinese Journal of Radiation Oncology, 2017, 26(5): 550-554.
[1] Rose PG,Bundy BN,Watkins EB,et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J].N Engl J Med,1999,340(15):1144-1153.DOI:10.1056/NEJM199904153401502. [2] Tanderup K,Eifel PJ,Yashar CM,et al. Curative radiation therapy for locally advanced cervical cancer:brachytherapy is NOT optional[J].Int J Radiat Oncol Biol Phys,2014,88(3):537-539.DOI:10.1016/j.ijrobp.2013.11.011. [3] Shin KH,Kim TH,Cho JK,et al. CT-guided intracavitary radiotherapy for cervical cancer:Comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose-volume parameters[J].Int J Radiat Oncol Biol Phys,2006,64(1):197-204.DOI:10.1016/j.ijrobp.2005.06.015. [4] Potter R,Georg P,Dimopoulos JC,et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer[J].Radiother Oncol,2011,100(1):116-123.DOI:10.1016/j.radonc.2011.07.012. [5] Charra-Brunaud C,Harter V,Delannes M,et al. Impact of 3 d image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France:Results of the French STIC prospective study[J].Radiother Oncol,2012,103(3):305-313.DOI:10.1016/j.radonc.2012.04.007. [6] Haie-Meder C,Potter R,van Limbergen E,et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (i):concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J].Radiother Oncol,2005,74(3):235-245.DOI:10.1016/j.radonc.2004.12.015. [7] Mayr NA,Tali ET,Yuh WT,et al. Cervical cancer:application of MR imaging in radiation therapy[J].Radiology,1993,189(2):601-608.DOI:10.1148/radiology.189.2.8210395. [8] Viswanathan AN,Erickson B,Gaffney DK,et al. Comparison and consensus guidelines for delineation of clinical target volume for CT-and MR-based brachytherapy in locally advanced cervical cancer[J].Int J Radiat Oncol Biol Phys,2014,90(2):320-328.DOI:10.1016/j.ijrobp.2014.06.005. [9] Viswanathan AN,Dimopoulos J,Kirisits C,et al. Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy:Results of a prospective trial and preliminary guidelines for standardized contours[J].Int J Radiat Oncol Biol Phys,2007,68(2):491-498.DOI:10.1016/j.ijrobp.2006.12.021. [10] Wakatsuki M, Ohno T,Yoshida D,et al. Intracavitary combined with CT-guided interstitial brachytherapy for locally advanced uterine cervical cancer:introduction of the technique and a case presentation[J].J Radiat Res,2011,52(1):54-58.DOI:10.1269/jrr.10091. [11] Martinez A,Cox RS Edmundson GK.A multiple-site perineal applicator (MUPIT) for treatment of prostatic,anorectal,and gynecologic malignancies[J].Int J Radiat Oncol Biol Phys,1984,10(2):297-305.DOI:10.1016/0360-3016(84)90016-6. [12] Erickson B,Albano K,Gillin M.CT-guided interstitial implantation of gynecologic malignancies[J].Int J Radiat Oncol Biol Phys,1996,36(3):699-709.DOI:10.1016/S0360-3016(96)00373-2. [13] Kirisits C,Lang S,Dimopoulos J,et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:Design,application,treatment planning,and dosimetric results[J].Int J Radiat Oncol Biol Phys,2006,65(2):624-630.DOI:10.1016/j.ijrobp.2006.01.036. [14] Nomden CN,de Leeuw AA,Moerland MA,et al. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer[J].Int J Radiat Oncol Biol Phys,2012,82(4):1424-1430.DOI:10.1016/j.ijrobp.2011.04.044. [15] Fokdal L,Tanderup K,Hokland SB,et al. Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component[J].Radiother Oncol,2013,107(1):63-68.DOI:10.1016/j.radonc.2013.01.010. [16] Lindegaard JC,Tanderup K.Counterpoint:Time to retire the parametrial boost[J].Brachytherapy,2012,11(2):80-83.DOI:10.1016/j.brachy.2012.01.004. [17] Viswanathan AN,Beriwal S,de Los Santos JF,et al. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part Ⅱ:High-dose-rate brachytherapy[J].Brachytherapy,2012,11(1):47-52.DOI:10.1016/j.brachy.2011.07.002. [18] Dimopoulos JC,Lang S,Kirisits C,et al. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy[J].Int J Radiat Oncol Biol Phys,2009,75(1):56-63.DOI:10.1016/j.ijrobp.2008.10.033. [19] Levitchi M,Charra-Brunaud C,Quetin P,et al. Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3 d pulse-dose-rate intracavitary brachytherapy[J].Radiother Oncol,2012,103(3):314-321.DOI:10.1016/j.radonc.2012.04.008. [20] Dimopoulos JC,Kirisits C,Petric P,et al. The vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:Clinical feasibility and preliminary results[J].Int J Radiat Oncol Biol Phys,2006,66(1):83-90.DOI:10.1016/j.ijrobp.2006.04.041.
2017, Vol. 26 
